Diagnosis, Treatment, and Prognosis of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in Adults
JAMA Clinical Reviews
00:00
Tolvaptan in ADPKD Treatment
This chapter explores the use of Tolvaptan, a V2 receptor antagonist, in managing Autosomal Dominant Polycystic Kidney Disease (ADPKD) by inhibiting vasopressin action to reduce cyst growth. It emphasizes the critical need for early intervention to preserve kidney function and discusses the associated risks, including liver toxicity.
Transcript
Play full episode
